Why the study?
Residual risk remains high in patients surviving 1 year after ACS, and prolonged antithrombotic therapy to reduce ischemic risk must be balanced against increased bleeding risk.
Do antithrombotic options beyond 1 year (prolonged DAPT or low-dose rivaroxaban with aspirin) reduce residual cardiovascular risk in patients surviving 1 year after ACS?
Do antithrombotic options beyond 1 year (prolonged DAPT or low-dose rivaroxaban with aspirin) reduce residual cardiovascular risk in patients surviving 1 year after ACS?
This review highlights that extending antithrombotic therapy beyond 1 year post-ACS reduces ischemic events but increases bleeding, emphasizing the need for individualized risk assessment.
Answers are grounded in this paper and cite their sources.
Requires individualized risk assessment for extended antithrombotic therapy post-ACS; leaves open optimal agent and duration in modern cohorts.
The residual risk of patients surviving until 1 year after acute coronary syndromes (ACS) is still high, despite secondary prevention. The cornerstone of treatment of patients with ACS is dual antiplatelet therapy (DAPT) consisting of low-dose aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) for 12 months, or less in those patients at higher risk for bleeding. To reduce the residual risk beyond 1 year in those patients not at high bleeding risk who tolerated DAPT and did not suffer an (ischaemic or bleeding) event would intuitively mean to prolong DAPT. However, prolonged DAPT always comes at the cost of more bleeding. Therefore, assessing both ischaemic and bleeding risk in these patients at 1 year after ACS is crucial. In addition, another antithrombotic treatment consisting of low-dose rivaroxaban combined with low-dose aspirin has been shown to reduce ischaemic events. In this review, we describe residual thrombotic risk at 1 year after ACS, evaluate the evidence for antithrombotic options beyond 1 year and provide a practical guide to determine which patients would benefit the most from these therapies.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: